読み込み中
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
前日終値
$19.78
+$0.20 · +1.02%
日中の時刻はETです。市場データは遅延する場合があります。
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
日中レンジ
現在 $19.78
52週レンジ
現在 $19.78
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
91
大幅な割安
センチメント
80
強気
リスク
28
中程度のリスク
モメンタム
59
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
日中レンジ
現在 $19.78
52週レンジ
現在 $19.78
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 10.72億 USD | 9.58億 USD | 7.26億 USD | 5.17億 USD | 4.84億 USD |
| 売上原価 | 8899.8万 USD | 8184.1万 USD | 4573.1万 USD | 1016.6万 USD | 1914.1万 USD |
| 粗利益 | 9.83億 USD | 8.76億 USD | 6.81億 USD | 5.07億 USD | 4.65億 USD |
| 研究開発 | 3.29億 USD | 3.03億 USD | 3.52億 USD | 3.62億 USD | 2.39億 USD |
| 販売・一般管理 | 5.49億 USD | 4.88億 USD | 4.02億 USD | 3.69億 USD | 3.96億 USD |
| 営業費用 | 8.78億 USD | 6.45億 USD | 7.54億 USD | 7.31億 USD | 6.35億 USD |
| 受取利息 | 3172.2万 USD | 2545.8万 USD | 1723.4万 USD | 661万 USD | 59.1万 USD |
| 減価償却費と償却費 | 1176万 USD | 1588.3万 USD | 555.2万 USD | 202.6万 USD | 334.4万 USD |
| 営業利益 | 1.05億 USD | 2.31億 USD | −7337.9万 USD | −2.24億 USD | −1.7億 USD |
| 純利益 | 3.91億 USD | 2.26億 USD | −6128.6万 USD | −2.16億 USD | −1.68億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$32.32
上昇余地（63.40%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1.18億0.01%2.3兆 USD0.03%$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB8552.4万0.05%1853億 USD0.03%$289.48+0.64%
iShares Russell 2000 ETFIWM6629.06万0.08%787.4億 USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap Growth ETFVBK4912.76万0.11%447億 USD0.05%$344.74+1.22%
State Street SPDR S&P Biotech ETFXBI4906.58万0.50%98.74億 USD0.35%$153.77+3.00%
Vanguard Extended Market ETFVXF4259.11万0.04%954億 USD0.05%$235+0.80%
iShares Biotechnology ETFIBB2580.27万0.25%108.2億 USD0.44%$206.49+3.00%
Dimensional - US Small Cap ETFDFAS2371.03万0.07%338.69億 USD0.31%$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Growth ETFVBKState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
